Early Warning Signs of OCD You Should Never Ignore

Share this post:

LinkedIn
Facebook
X
Reddit
WhatsApp
Print

The early signs of OCD usually show up in three patterns. You may notice intrusive thoughts that repeat and feel hard to shut off, repetitive actions or mental rituals that bring short relief, and rising reassurance seeking or avoidance that starts to shape your day. OCD is defined by obsessions, compulsions, or both, and symptoms often begin between late childhood and young adulthood.

People often miss early OCD because the first signs can look like caution, stress, overthinking, or a strong preference for order. The difference is in the intensity, repetition and time cost. Clinical guidance describes obsessions as intrusive unwanted thoughts, urges, or mental images, and compulsions as repetitive behaviors or mental acts performed to reduce distress or prevent a feared event.

If you are looking for early warning signs, pay close attention to patterns that feel sticky, time consuming and hard to resist. Those patterns often appear before a formal diagnosis and can start to interfere with school, work, sleep, relationships and routine tasks.

Mental loops and intrusive thought patterns

One of the clearest early signs is a mental loop that keeps returning even when you know it does not make sense to stay with it. Common early patterns include the following.

1. Repeated unwanted thoughts that feel alarming

You may get the same fear, image, urge, or doubt again and again. It may center on contamination, harm, mistakes, morality, religion, sex, or a need for things to feel exact. These thoughts tend to feel intrusive and unwanted rather than chosen.

2. A strong sense that the thought needs an answer right away

Early OCD often creates urgency. You may feel that you must solve the doubt now, check the memory now, or settle the fear before you can move on. That pressure is part of what makes the loop different from an ordinary passing worry.

3. Difficulty trusting your own memory or perception

You may know you locked the door, sent the message, washed your hands, or turned off the stove, but the doubt returns within minutes. Early checking symptoms often grow from this repeated loss of confidence in what you just did.

4. Silent mental rituals

Not all early compulsions are visible. You may count in your head, repeat phrases silently, review events, pray in a rigid way, or mentally cancel a thought to bring down fear. Clinical guidance includes mental acts within the definition of compulsions.

5. Distress tied to themes that clash with your values

Intrusive thoughts in OCD often target the areas of life that feel most sensitive to you. That can include safety, honesty, faith, sexuality, morality, health, or responsibility for others. The content can feel disturbing because it hits close to what you care about.

6. Trouble letting a thought fade on its own

A common early sign is feeling unable to leave the thought alone. You may keep testing it, replaying it, arguing with it, or trying to force certainty. This can turn a short fear spike into a long cycle that keeps restarting.

7. Growing time loss from internal rumination

Early OCD can eat up time before anyone else notices a problem. A person may spend long stretches thinking through the same scenario, reviewing what they said, checking their reaction, or trying to feel fully certain before moving on. Symptoms can become time consuming and interfere with daily functioning.

Physical compulsions and repetitive daily actions

The next sign cluster shows up in what you do with your body, your environment and your routine. These actions may look small at first, then build into longer daily rituals.

8. Repeated checking

You may check locks, appliances, bags, schoolwork, emails, medications, or your body over and over. The first check may feel reasonable. The later checks are often driven by a sense that the risk still feels unfinished.

9. Repetitive washing or cleaning

Frequent handwashing, showering, sanitizing, laundering, or surface cleaning can be an early sign when it is driven by distress rather than ordinary hygiene. NIMH lists contamination fears and washing compulsions among common OCD symptoms.

10. Arranging, ordering, or repeating until it feels right

Some early cases start with a need for symmetry, exactness, or a “just right” feeling. You may rearrange items, even out body movements, restart tasks, or repeat a motion until the internal tension drops.

11. Touching, tapping, or counting routines

Touching a surface a certain number of times, walking in a set pattern, counting steps, or following private number rules can all fall within OCD compulsions when they are used to reduce distress or prevent a feared outcome.

12. Long delays in finishing ordinary tasks

Getting dressed, leaving the house, sending a text, putting groceries away, or going to bed may start taking much longer than they used to. The delay often comes from repeated checking, restarting, cleaning, or trying to make the action feel complete.

13. Skin irritation, fatigue, or physical strain from rituals

Repeated washing can irritate skin. Repeated checking and restarting can interfere with sleep and drain energy. Clinical guidance also notes that OCD can reduce quality of life and interfere with work, school and relationships.

14. Hiding behaviors from other people

Many people with early OCD try to conceal rituals out of shame or fear of being judged. You may wait until you are alone to recheck something, clean in secret, or do mental rituals silently during conversations. Hidden symptoms can delay recognition and treatment.

Reassurance seeking and avoidance behaviors

A third early warning cluster shows up in the ways you try to feel safe by using other people, staying away from triggers, or narrowing your routine.

15. Repeated reassurance seeking

You may ask the same question many times, even after getting a clear answer. This can include asking if you offended someone, asking if a risk is real, or asking another person to confirm that an object is safe, clean, locked, or correct. Reassurance can function like a compulsion because it brings brief relief and then has to be repeated.

16. Avoiding places, objects, or situations tied to the obsession

You may stop touching shared surfaces, stop driving, avoid knives, avoid news, avoid children, avoid religious settings, or avoid being alone with your own thoughts. Avoidance can look protective at first, but it often lets the fear stay strong.

17. Needing another person to participate in your routine

Family members or partners may start helping you check, clean, answer repeated questions, or follow rules designed to reduce your distress. Clinical guidance notes that loved ones can begin accommodating OCD symptoms, which can keep the cycle going.

18. Shrinking daily life to avoid uncertainty

A strong early sign is that your day starts getting built around feeling safe enough to function. You may leave less often, carry out the same routine in the same order, avoid spontaneous plans, or put off tasks that carry even a small chance of doubt or discomfort.

19. Rising shame about your own thoughts or rituals

People with early OCD often feel embarrassed by the content of their thoughts or by the amount of time rituals take. Shame can make symptoms more private, which often makes outside help less likely in the early stage.

20. Symptoms taking more than an hour a day or clearly interfering with life

This is one of the strongest signals that the pattern has moved into clinical territory. Formal diagnosis often looks at time burden, distress and functional impairment. If thoughts or rituals are taking up large parts of the day or disrupting work, school, sleep, family life, or self care, that is a serious sign that should not be brushed aside.

Early signs do not always appear in the same order. Some people first notice intrusive taboo thoughts. Others first notice washing, checking, symmetry rituals, or repeated reassurance seeking. The content can differ a lot, but the shared clinical thread is repetition, distress and the sense of being driven to respond.

Conclusion

Early intervention can affect long term outcomes, and we at Rose Hill Life Sciences are dedicated to building a foundation for better clinical options. We are a psychedelic research organization specializing in the production and research of Psilocybe cubensis, operating at the intersection of science and therapeutic integration, and are based in Massachusetts.




Disclaimer: The information in this article is for educational and informational purposes only and does not constitute medical advice.

You May Also Like

Adam Goodman

Advisor

Adam is a seasoned entrepreneur with a wealth of experience in spearheading real estate development and management endeavors. His focus primarily lies in land development, where he orchestrates the intricate tapestry of planning and zoning entitlements, while meticulously overseeing all facets of engineering and architectural design, leasing, construction, and financing.

With a national reach spanning 23 states and encompassing over 250 properties, totaling more than 6 million square feet, Adam’s proficiency in navigating the complexities of the industry is evident.

Beyond real estate, Adam’s endeavors extend into the realm of alternative investments, boasting successful ventures in healthcare, professional sports franchises, financial services, diverse agricultural platforms, and the stewardship of local restaurants.

 

Rotem Petranker, PhD, Psychology

Psychedelic Researcher

Rotem Petranker is a psychedelics researcher with a particular emphasis on microdosing, therapy, research methods and research ethics. He earned his BSc from the University of Toronto, his Master’s degree from York University, and his PhD from McMaster University.

As part of my research, I have gained extensive expertise in navigating the regulatory landscapes of Health Canada and the FDA and a strong background in designing rigorous clinical trial research methodologies. 

I founded the Canadian Centre for Psychedelic Science in 2018, established the Psychedelic Science Research Program at the University of Toronto in 2019, and, more recently, ran the largest clinical trial to date on the effectiveness of microdosing psilocybin for Major Depressive Disorders. I have published many papers on microdosing, including some of the largest samples in the literature and some that have set standards for performing psychedelic research.

Kevin Bourke

Chief Commercial Officer

Kevin Bourke is a dynamic executive and strategic planner whose career spans over two decades of crafting and elevating world-class Jamaican brands and transformational experiences on the global stage. With a keen understanding of culture, identity, and international markets, he has played a pivotal role in shaping some of Jamaica’s most iconic names — including Appleton Estate Rum, Chris Blackwell’s Rum, and Usain Bolt’s Tracks & Records — bringing them from local roots to international acclaim. His leadership and vision have also been instrumental in major cultural movements such as Fiction and the internationally recognized TmrwTday Wellness Festival.

An innovator at heart, Mr. Bourke seamlessly blends brand strategy with deep cultural resonance. His ability to connect with diverse audiences has established these brands not only as commercial successes but as symbolic ambassadors of Jamaican excellence, fortifying the island’s influence in beverage, music, lifestyle, and experiential sectors.

In recent years, Kevin has steered his strategic acumen toward the cutting-edge psilocybin and wellness industry, becoming a co-founder and Chief Marketing and Branding Officer of Rose Hill, Jamaica’s leading cultivator, exporter, and innovator of psilocybin products and experiences. Through ventures like ONE Retreats, he has helped craft safe, guided psychedelic-assisted healing programs that attract participants from around the world seeking deep personal transformation, including military veterans and international wellness seekers.

Kevin’s impact extends beyond business into industry shaping and policy, as he sits on the Jamaica Psilocybin Mushroom Industry Technical Committee (under the Bureau of Standards) — a pivotal body that is formalizing guidelines and regulatory standards for the emerging legal psilocybin sector in Jamaica. His presence on this committee underscores his leadership role in ensuring the industry’s integrity, safety, and sustainable growth.

Highly regarded for his extensive network throughout Jamaica and internationally, Kevin remains passionately committed to advancing ethical, high-integrity product development and customer-centric experiences at every level. His dedication is driven not only by professional achievement but by a deep vision for human well-being, cultural celebration, and the global evolution of plant-based healing.

Jama Pitman

Regulatory Strategy

Jama Pitman is a seasoned biopharmaceutical executive with extensive expertise in global drug development and commercialization. With over two decades of experience, she has contributed to the development of groundbreaking therapies across oncology, rare diseases, and antivirals. As a strategic leader, she has successfully transitioned companies from private to public markets, navigated complex M&A transactions, and driven innovative drug approvals.

Jama has held executive roles in leading organizations, including Deciphera Pharmaceuticals, where she played a pivotal role in scaling operations from a small, privately held biotech company to a global, multi-product company acquired for $2.4 billion. She brings exceptional skills in regulatory affairs, portfolio management, quality assurance, and clinical operations, longside a proven track record of fostering inclusivity and mentorship within her teams.

Currently, as the founder of JP BioPharma Consulting, Jama advises biopharma and tech companies on accelerating drug development and achieving corporate goals. Her collaborative and forward-thinking approach aligns seamlessly with Rose Hill’s mission to advance transformative therapies in mental health and beyond.

Education: B.Sc. in Microbiology, University of New Hampshire.

Notable Achievements: Contributed to the development of multiple FDA-approved therapies, including QINLOCK® for gastrointestinal stromal tumors.

Domenic Suppa

Chief Operating Officer

Domenic is co-founder and the Operations Chief of Rose Hill Health Holdings.

He has been working as a Cannabis technology and operations veteran with more than 11 years’ experience as a senior executive in an operationally complex, and highly regulated industry.

His introduction and entrance into the Cannabis sector started in 2010 with a seed investment into a Denver-based vertically integrated cannabis company called, Evolab. He served as C.O.O. for 5 years from 2013-2018, through the eventual acquisition by Harvest Health and Recreation (HARV: CSE).

Domenic moved on to be acting COO of the manufacturing division for Supreme Cannabis (CSE: FIRE) and supported the acquisition of BLISSCO (CSE: BLISS, a BC-based cannabis manufacturer). Domenic has worked with high-profile national cannabis brands including KKE, and Monogram, and retail brands in MA Native Sun, Terps, and Tilt. Domenic is a proven leader and team builder; his previous experiences have all been with early-stage and growth equity enterprises.

He has refined and evolved his leadership roles, including his team-building skills. He is a value creator. Domenic is a firm believer in training and continuous development. He excels in employing practices, tools, and methodologies designed to achieve maximum process efficiency while minimizing waste and delays.

 

Burton J. Tabaac

Clinical Development

Dr. Burton J. Tabaac, MD, FAHA, brings a wealth of expertise in neurology and stroke rehabilitation to Rose Hill. As an Associate Professor and Section Chief of Neurology at The University of Nevada’s Reno School of Medicine, and Medical Director of Stroke at Carson Tahoe Health, Dr. Tabaac has been at the forefront of innovative neurological treatments.

A graduate of the prestigious cerebrovascular neurology fellowship program at The Johns Hopkins University Hospital, Dr. Tabaac’s accolades include being a three-time recipient of The Arnold P. Gold Foundation’s Humanism and Excellence in Teaching Award and induction into the Alpha Omega Alpha Honor Medical Society.

He recently published an eight-part paper in the American Journal of Therapeutics reviewing psychedelics as therapeutics for primary care clinicians. Dr. Tabaac’s groundbreaking research focuses on the application of psychedelics in brain injury and stroke rehabilitation.

Dr. Tabaac was recently appointed by the Governor of Nevada to serve as a member of the state’s Psychedelic Medicines Working Group, which provides expertise and testimony relating to the therapeutic use of entheogens.

As the host of The Zero Hour Podcast, he engages with leading experts in psychedelic research. His commitment to advancing the field was further highlighted in his 2022 TEDx talk at UCLA, “Mental Health Meets Psychedelics.”

“Joining Rose Hill’s advisory team presents an exciting opportunity to further explore the potential of psilocybin in neurological recovery,” said Dr. Tabaac.

“The company’s commitment to ethical cultivation and research aligns perfectly with my vision for advancing patient care through innovative therapies. I’m eager to bring my expertise to Rose Hill and contribute to the evolving landscape of psychedelic medicine.”

Charles Lazarus

Chief Executive Office

Mr. Lazarus boasts over 16 years of extensive expertise in psilocybin and cannabis, focusing on genetic development, cultivation, extraction, and operations logistics. Notably, he recently achieved a milestone by cultivating and delivering the largest legal shipment of premium psilocybin globally.

As an accomplished owner/operator, Mr. Lazarus has successfully managed multiple farming and harvesting businesses, earning commendations for his unwavering commitment to quality and impressive output volumes. Since 2015, he has been actively involved in producing proprietary psilocybin genetics and cultivation solutions tailored for the Jamaican market and large research and development clients.

His contributions span various aspects, including genetic development, cultivation, extraction, harvest, and logistics. Additionally, Mr. Lazarus owned and operated Island Fresh Ltd., a venture that played a pivotal role in exporting fresh fruit, ground provisions, and promoting brand Jamaica to the English market. Under his leadership, Island Fresh Ltd. achieved the highest volume from Jamaica for three consecutive years.

Mr. Lazarus’s extensive experience also includes serving as the Harvest Manager for cannabis grow operations in California from 2013 to 2017, further solidifying his comprehensive knowledge in the cannabis industry.